Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM.

J Clin Oncol. 2010 Sep 1;28(25):3910-6. doi: 10.1200/JCO.2009.27.3615. Epub 2010 Aug 2.

PMID:
20679614
[PubMed - indexed for MEDLINE]
Free Article
2.

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ.

J Clin Oncol. 2005 Nov 1;23(31):7820-6.

PMID:
16258084
[PubMed - indexed for MEDLINE]
Free Article
3.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A.

Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24.

PMID:
23349345
[PubMed - indexed for MEDLINE]
4.

High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.

Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.

Breast Cancer Res Treat. 2012 Jul;134(1):291-8. doi: 10.1007/s10549-012-2039-z. Epub 2012 Apr 4.

PMID:
22476854
[PubMed - indexed for MEDLINE]
5.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID:
16258083
[PubMed - indexed for MEDLINE]
Free Article
6.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
[PubMed - indexed for MEDLINE]
7.

Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L.

J Clin Oncol. 2006 Jun 20;24(18):2773-8. Epub 2006 May 8.

PMID:
16682726
[PubMed - indexed for MEDLINE]
Free Article
8.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
[PubMed - indexed for MEDLINE]
9.

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.

Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603. Epub 2012 Jun 28.

PMID:
22744937
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.

Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.

J Am Coll Cardiol. 2011 May 31;57(22):2263-70. doi: 10.1016/j.jacc.2010.11.063.

PMID:
21616287
[PubMed - indexed for MEDLINE]
Free Article
11.

Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.

Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT.

Clin Cancer Res. 2011 May 15;17(10):3490-9. doi: 10.1158/1078-0432.CCR-10-1359. Epub 2011 Mar 3.

PMID:
21372222
[PubMed - indexed for MEDLINE]
Free Article
12.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

PMID:
16710024
[PubMed - indexed for MEDLINE]
Free Article
13.

Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.

Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network.

J Card Fail. 2012 Feb;18(2):113-9. doi: 10.1016/j.cardfail.2011.10.015. Epub 2011 Dec 3.

PMID:
22300778
[PubMed - indexed for MEDLINE]
14.

Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer.

Russo G, Cioffi G, Di Lenarda A, Tuccia F, Bovelli D, Di Tano G, Alunni G, Gori S, Faggiano P, Tarantini L.

Intern Emerg Med. 2012 Oct;7(5):439-46. Epub 2012 Jun 20.

PMID:
22714882
[PubMed - indexed for MEDLINE]
15.

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F.

Clin Breast Cancer. 2007 Aug;7(9):690-6.

PMID:
17919349
[PubMed - indexed for MEDLINE]
16.

Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.

Naumann D, Rusius V, Margiotta C, Nevill A, Carmichael A, Rea D, Sintler M.

Anticancer Res. 2013 Apr;33(4):1717-20.

PMID:
23564821
[PubMed - indexed for MEDLINE]
17.

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.

Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM.

Clin Cancer Res. 2008 May 1;14(9):2710-6. doi: 10.1158/1078-0432.CCR-07-4636. Erratum in: Clin Cancer Res. 2008 Jun 1;14(11):3641.

PMID:
18451236
[PubMed - indexed for MEDLINE]
Free Article
18.

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ.

J Clin Oncol. 2006 Sep 1;24(25):4107-15. Epub 2006 Aug 14. Erratum in: J Clin Oncol. 2008 May 10;26(14): 2421.

PMID:
16908934
[PubMed - indexed for MEDLINE]
Free Article
19.

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA.

Clin Breast Cancer. 2006 Aug;7(3):237-43.

PMID:
16942640
[PubMed - indexed for MEDLINE]
20.

[Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].

Menke-van der Houven van Oordt CW, Fliervoet HJ, Mandigers CM, van Spronsen DJ.

Ned Tijdschr Geneeskd. 2008 Jan 19;152(3):158-63. Dutch.

PMID:
18271465
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk